A new trading day began on June 23, 2022, with Cardiff Oncology Inc. (NASDAQ: CRDF) stock priced at $1.74, up 31.61% from the previous day of trading. During the day, the shares moved up to $2.33 and dropped to $1.7006 before settling in for the closing price of $1.74. CRDF’s price has ranged from $1.13 to $8.58 over the past 52 weeks.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
During the last 5-year period, the sales drop of Healthcare Sector giant was -1.20%. Meanwhile, its annual earnings per share averaged 33.00%. With a float of $40.22 million, this company’s outstanding shares have now reached $43.23 million.
Let’s determine the extent of company efficiency that accounts for 22 employees. In terms of profitability, gross margin is -39.28, operating margin of -8037.60, and the pretax margin is -7880.50.
Cardiff Oncology Inc. (CRDF) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Cardiff Oncology Inc. is 7.12%, while institutional ownership is 43.40%. The most recent insider transaction that took place on Sep 21, was worth 202,500. In this transaction Director of this company bought 30,000 shares at a rate of $6.75, taking the stock ownership to the 494,811 shares. Before that another transaction happened on Sep 10, when Company’s Chief Financial Officer bought 30,000 for $6.47, making the entire transaction worth $194,000. This insider now owns 30,000 shares in total.
Cardiff Oncology Inc. (CRDF) Earnings and Forecasts
In its latest quarterly report, released on 3/30/2022, the company reported earnings of -$0.25 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). This company achieved a net margin of -7880.50 while generating a return on equity of -20.89. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.27 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 33.00% per share during the next fiscal year.
Cardiff Oncology Inc. (NASDAQ: CRDF) Trading Performance Indicators
Here are Cardiff Oncology Inc.’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 20.40. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 236.10.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.84, a number that is poised to hit -0.25 in the next quarter and is forecasted to reach -1.45 in one year’s time.
Technical Analysis of Cardiff Oncology Inc. (CRDF)
Looking closely at Cardiff Oncology Inc. (NASDAQ: CRDF), its last 5-days average volume was 1.03 million, which is a jump from its year-to-date volume of 0.86 million. As of the previous 9 days, the stock’s Stochastic %D was 47.77%. Additionally, its Average True Range was 0.23.
During the past 100 days, Cardiff Oncology Inc.’s (CRDF) raw stochastic average was set at 43.81%, which indicates a significant decrease from 88.39% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 203.25% in the past 14 days, which was higher than the 112.68% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.5100, while its 200-day Moving Average is $4.0500. However, in the short run, Cardiff Oncology Inc.’s stock first resistance to watch stands at $2.5100. Second resistance stands at $2.7400. The third major resistance level sits at $3.1400. If the price goes on to break the first support level at $1.8800, it is likely to go to the next support level at $1.4800. Should the price break the second support level, the third support level stands at $1.2500.
Cardiff Oncology Inc. (NASDAQ: CRDF) Key Stats
With a market capitalization of 94.44 million, the company has a total of 43,306K Shares Outstanding. Currently, annual sales are 360 K while annual income is -28,290 K. The company’s previous quarter sales were 70 K while its latest quarter income was -10,990 K.